Richard Bartfai, theme Infectious diseases and global health, and Clemens Kocken (BPRC) received 675,000 euros from ZonMw to uncover the molecular mechanisms underlying dormancy of malaria parasites, a major obstacle to efficient treatment of Plasmodium vivax malaria.Plasmodium vivax causes severe morbidity in Asia and South-America and is regarded as a major challenge to malaria elimination. The biggest obstacle in fighting P. vivax is the presence of dormant parasites. These, so called, hypnozoites can stay dormant in the liver without any symptoms for weeks to years, survive treatment of blood stage infection and reactivate causing malaria without renewed exposure to infected mosquitos. In order to better target hypnozoites, it is important to unravel the mechanisms behind their dormancy and reactivation. Hypnozoites, however, have long been inaccessible for experimental investigations and hence represent a major knowledge gap in our understanding of the parasite’s life cycle, which in turn hinders drug development.
Therefore, in this project, Clemens Kocken and Richard Bartfai will form a powerful partnership to combine state-of-the-art genomic technologies and a unique transgenic model system to understand mechanisms that drive liver stage parasites into dormancy or dictate their reactivation. These insights may prove essential to further vivax malaria control and elimination by paving the way for new and innovative approaches to target this critical human pathogen.
Related news items
Step-up approach vs open necrosectomy for necrotizing pancreatitis18 April 2019
Another publication of the successful Dutch collaborative group on pancreatitis research with substantial contribution from Radboudumc researchers, Harry van Goor and Kees van Laarhoven.read more
Prophylactic antibiotics reduce hospitalisations and cost in head and neck cancer patients18 April 2019
In European journal of cancer Janneke Ham and colleagues showed that prophylactic antibiotics in locally advanced head and neck cancer patients treated with chemoradiotherapy did not reduce the incidence of (aspiration) pneumonias, but did reduce hospitalisations and tended to be cost-effective.read more
Nontuberculous mycobacteria and fungal co-infections Bonnie and Clyde?18 April 2019
In The European respiratory journal Jakko van Ingen and Sanne Zweijpfenning showed that 40% of patients diagnosed with nontuberculous mycobacterial pulmonary disease also meet diagnostic criteria for chronic pulmonary aspergillosis.read more
ESCMID award for groundbreaking studies on NTM disease18 April 2019
Jakko van Ingen received the ESCMID Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease.read more
EU funded project BIOMAP led by Ellen van den Bogaard12 April 2019
Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.read more